These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 27603796)

  • 1. Activating the innate immune response to counter chronic hepatitis B virus infection.
    Lamb C; Arbuthnot P
    Expert Opin Biol Ther; 2016 Dec; 16(12):1517-1527. PubMed ID: 27603796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
    Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.
    Lanford RE; Guerra B; Chavez D; Giavedoni L; Hodara VL; Brasky KM; Fosdick A; Frey CR; Zheng J; Wolfgang G; Halcomb RL; Tumas DB
    Gastroenterology; 2013 Jun; 144(7):1508-17, 1517.e1-10. PubMed ID: 23415804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus: new therapeutic perspectives.
    Lin CL; Yang HC; Kao JH
    Liver Int; 2016 Jan; 36 Suppl 1():85-92. PubMed ID: 26725903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells.
    Li L; Barry V; Daffis S; Niu C; Huntzicker E; French DM; Mikaelian I; Lanford RE; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):912-921. PubMed ID: 29247724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The current status and future directions of hepatitis B antiviral drug discovery.
    Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT
    Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.
    Ma Z; Zhang E; Yang D; Lu M
    Cell Mol Immunol; 2015 May; 12(3):273-82. PubMed ID: 25418467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control and Eradication Strategies of Hepatitis B Virus.
    Shih C; Chou SF; Yang CC; Huang JY; Choijilsuren G; Jhou RS
    Trends Microbiol; 2016 Sep; 24(9):739-749. PubMed ID: 27287929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: novel therapies for hepatitis B virus cure - advances and perspectives.
    Lin CL; Kao JH
    Aliment Pharmacol Ther; 2016 Aug; 44(3):213-22. PubMed ID: 27302653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B.
    Menne S; Tumas DB; Liu KH; Thampi L; AlDeghaither D; Baldwin BH; Bellezza CA; Cote PJ; Zheng J; Halcomb R; Fosdick A; Fletcher SP; Daffis S; Li L; Yue P; Wolfgang GH; Tennant BC
    J Hepatol; 2015 Jun; 62(6):1237-45. PubMed ID: 25559326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line.
    Das D; Sengupta I; Sarkar N; Pal A; Saha D; Bandopadhyay M; Das C; Narayan J; Singh SP; Chakrabarti S; Chakravarty R
    BMC Infect Dis; 2017 Jan; 17(1):76. PubMed ID: 28088184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agonistic Activation of Cytosolic DNA Sensing Receptors in Woodchuck Hepatocyte Cultures and Liver for Inducing Antiviral Effects.
    Suresh M; Li B; Huang X; Korolowicz KE; Murreddu MG; Gudima SO; Menne S
    Front Immunol; 2021; 12():745802. PubMed ID: 34671360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx.
    Cheng ST; Hu JL; Ren JH; Yu HB; Zhong S; Wai Wong VK; Kwan Law BY; Chen WX; Xu HM; Zhang ZZ; Cai XF; Hu Y; Zhang WL; Long QX; Ren F; Zhou HZ; Huang AL; Chen J
    J Hepatol; 2021 Mar; 74(3):522-534. PubMed ID: 32987030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for Chronic Hepatitis B Virus Infection.
    Bertoletti A; Le Bert N
    Gut Liver; 2018 Sep; 12(5):497-507. PubMed ID: 29316747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis.
    Xia Y; Stadler D; Lucifora J; Reisinger F; Webb D; Hösel M; Michler T; Wisskirchen K; Cheng X; Zhang K; Chou WM; Wettengel JM; Malo A; Bohne F; Hoffmann D; Eyer F; Thimme R; Falk CS; Thasler WE; Heikenwalder M; Protzer U
    Gastroenterology; 2016 Jan; 150(1):194-205. PubMed ID: 26416327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection.
    Zhang X; Ma Z; Liu H; Liu J; Meng Z; Broering R; Yang D; Schlaak JF; Roggendorf M; Lu M
    J Hepatol; 2012 Sep; 57(3):522-8. PubMed ID: 22617154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
    Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
    Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
    Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
    Mutz P; Metz P; Lempp FA; Bender S; Qu B; Schöneweis K; Seitz S; Tu T; Restuccia A; Frankish J; Dächert C; Schusser B; Koschny R; Polychronidis G; Schemmer P; Hoffmann K; Baumert TF; Binder M; Urban S; Bartenschlager R
    Gastroenterology; 2018 May; 154(6):1791-1804.e22. PubMed ID: 29410097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear Sensor Interferon-Inducible Protein 16 Inhibits the Function of Hepatitis B Virus Covalently Closed Circular DNA by Integrating Innate Immune Activation and Epigenetic Suppression.
    Yang Y; Zhao X; Wang Z; Shu W; Li L; Li Y; Guo Z; Gao B; Xiong S
    Hepatology; 2020 Apr; 71(4):1154-1169. PubMed ID: 31402464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.